Aquestive Therapeutics, Inc. AQST Proprietary product revenue, net — Revenue
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Aquestive Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The official record: Aquestive Therapeutics, Inc.’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →
Ask your AI about Aquestive Therapeutics, Inc.'s proprietary product revenue, net — revenue.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Aquestive Therapeutics, Inc.'s proprietary product revenue, net — revenue?
- Aquestive Therapeutics, Inc. (AQST) reported proprietary product revenue, net — revenue of $0 in Q1 2026.
- How has Aquestive Therapeutics, Inc.'s proprietary product revenue, net — revenue changed year-over-year?
- Aquestive Therapeutics, Inc.'s proprietary product revenue, net — revenue decreased by 100.0% year-over-year, from $319K to $0.
- What does proprietary product revenue, net — revenue mean?
- This metric represents the net revenue generated from the sale of the company's internally developed and owned pharmaceutical products. It reflects the commercial success and market adoption of the firm's proprietary portfolio, excluding revenue derived from licensing or contract manufacturing arrangements. Tracking this figure helps investors evaluate the company's transition from a development-stage entity to a commercial-stage pharmaceutical business.